FDA's controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Sarepta’s regulatory win for Exondys51 (eteplirsen) left one group of analysts and FDA insiders more than a little flabbergasted.
There was only a minuscule …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
